Role of Immunotherapy for Small Cell Lung Cancer

tibbionko-17-1-kapak

Furkan CEYLANa , Mehmet Ali Nahit ŞENDURb
aAnkara Bilkent City Hospital, Clinic of Medical Oncology, Ankara, Türkiye
bAnkara Yıldırım Beyazıt University Faculty of Medicine, Ankara Bilkent City Hospital, Department of Medical Oncology, Ankara, Türkiye

Ceylan F, Şendur MAN. Role of immunotherapy for small cell lung cancer. In: Şendur MAN, ed. Current Immunotherapy Landscape for Solid Tumors. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.44-51.

ABSTRACT
Small-cell lung cancer (SCLC) account for approximately 14% of lung cancers. It was almost 100% associated with smoking. SCLC is a tumor with a short doubling time, therefore it grows rapidly and metastases develop early. For many years, the standard treatment for limited stage (LS) disease has been a combination of radiotherapy and doublet chemotherapy containing platinum salts. There are no phase 3 clinical studies in which ICIs have demonstrated a survival benefit. Clinical trials evaluating the efficacy of ICIs are ongoing in LS-SCLC. Chemotherapy forms the basis of advanced disease treatment. Addition of atezolizumab to chemotherapy in the Impower 133 trial, adding durvalumab to chemotherapy in the CASPIAN trial and adding serplulimab to chemotherapy in ASTRUM 005 trial has shown a survival benefit in first-line. ICIs may be appropriate for some patient groups in relapsed disease. The efficacy of nivolumab has been demonstrated in the second line of patients who are not suitable for chemotherapy. Nivolumab has been shown to provide a survival benefit in patients who have received at least two lines of therapy. Long duration of Response (DoR) has been shown to be obtained in PD-L1-positive patients who have received at least two lines of therapy and who achieved an objective response with pembrolizumab. While cytotoxic chemotherapy still serves as the cornerstone of disease care, significant progress is being made in the management of SCLC by creating new drugs, testing innovative combinations, and personalizing treatment.

Keywords: Small cell lung carcinoma; immunotherapy; atezolizumab; durvalumab; immune checkpoint inhibitors

Referanslar

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. [Crossref]  [PubMed]
  2. Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21(5):645-54. Erratum in: Lancet Oncol. 2020;21(12):e553. [Crossref]  [PubMed]
  3. Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44(10):1104-10. [Crossref]  [PubMed]  [PMC]
  4. Koyama K, Kagamu H, Miura S, Hiura T, Miyabayashi T, Itoh R, et al. Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res. 2008;14(21):6770-9. [Crossref]  [PubMed]
  5. Spigel DR, Socinski MA. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches. J Thorac Oncol. 2013;8(5):587-98. [Crossref]  [PubMed]
  6. Tani T, Tanaka K, Idezuka J, Nishizawa M. Regulatory T cells in paraneoplastic neurological syndromes. J Neuroimmunol. 2008;196(1-2):166-9. [Crossref]  [PubMed]
  7. Ruotsalainen T, Halme M, Isokangas OP, Pyrhönen S, Mäntylä M, Pekonen M, et al. Interferon-alpha and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer--a feasibility study. Anticancer Drugs. 2000;11(2):101-8. [Crossref]  [PubMed]
  8. Zarogoulidis K, Ziogas E, Papagiannis A, Charitopoulos K, Dimitriadis K, Economides D, et al. Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: a randomized trial. Lung Cancer. 1996;15(2):197-205. [Crossref]  [PubMed]
  9. Ragavan M, Das M. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy. Curr Treat Options Oncol. 2020;21(8):64. [Crossref]  [PubMed]
  10. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887-95. [Crossref]  [PubMed]  [PMC]
  11. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734-6. [Crossref]  [PubMed]
  12. Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjei AA. Current Diagnosis and Management of Small-Cell Lung Cancer. Mayo Clin Proc. 2019;94(8):1599-622. [Crossref]  [PubMed]
  13. Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021;39(6):619-630. [Crossref]  [PubMed]  [PMC]
  14. Goldman JW, Garassino MC, Chen Y, Reinmuth N, Hotta K, Poltoratskiy A et al. LBA86 Durvalumab (D) tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: characteri- zation of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN. Ann Oncol. 2020;31(Suppl 4):S1212-S3. [Crossref]
  15. Peters S, Pujol JL, Dafni U, Dómine M, Popat S, Reck M, et al.; ETOP/IFCT 4-12 STIMULI Collaborators. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. Ann Oncol. 2022;33(1):67-79. [Crossref]  [PubMed]
  16. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24(1):75-83. [Crossref]  [PubMed]
  17. Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, et al. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol. 2016;34(31):3740-8. Erratum in: J Clin Oncol. 2019;37(34):3327. [Crossref]  [PubMed]
  18. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al.; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929-39. [Crossref]  [PubMed]
  19. Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, et al.; KEYNOTE-604 Investigators. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020;38(21):2369-79. [Crossref]  [PubMed]  [PMC]
  20. Leal T, Wang Y, Dowlati A, Lewis DA, Chen Y, Mohindra AR, et al. Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. J Clin Oncol. 2020;38(15_Suppl):9000. [Crossref]
  21. Zhang S, Li S, Cheng Y. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis. Thorac Cancer. 2020;11(12):3536-46. [Crossref]  [PubMed]  [PMC]
  22. Brazel D, Ou SI, Nagasaka M. Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno. Lung Cancer (Auckl). 2023;14:1-9. [Crossref]  [PubMed]  [PMC]
  23. Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, et al.; ASTRUM-005 Study Group. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial. JAMA. 2022;328(12):1223-32. [Crossref]  [PubMed]  [PMC]
  24. Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, et al. Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. J Clin Oncol. 2021;39(12):1349-59. [Crossref]  [PubMed]  [PMC]
  25. Gadgeel SM, Pennell NA, Fidler MJ, Halmos B, Bonomi P, Stevenson J, et al. Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). J Thorac Oncol. 2018;13(9):1393-9. [Crossref]  [PubMed]  [PMC]
  26. Pujol JL, Greillier L, Audigier-Valette C, Moro-Sibilot D, Uwer L, Hureaux J, et al. A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial. J Thorac Oncol. 2019;14(5):903-13. [Crossref]  [PubMed]
  27. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883-95. Erratum in: Lancet Oncol. 2016;17(7):e270. Erratum in: Lancet Oncol. 2019;20(2):e70. [Crossref]  [PubMed]
  28. Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆. Ann Oncol. 2021;32(5):631-41. [Crossref]  [PubMed]
  29. Keeping ST, Cope S, Chan K, Wilson FR, Jansen JP, Penrod JR, et al. Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer. J Comp Eff Res. 2020;9(18):1275-84. [Crossref]  [PubMed]
  30. Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH Jr, et al. Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. J Thorac Oncol. 2020;15(4):618-27. [Crossref]  [PubMed]
  31. Owonikoko TK, Champiat S, Johnson ML, Govindan R, Izumi H, Lai WV, et al. Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC). J Clin Oncol 2021b;39(15_suppl):8510. [Crossref]
  32. Ahn MJ. New agents in the management of small cell lung cancer. American Society of Clinical Oncology. 2021 Annual Meeting, June.
  33. Wong SK, Whisenant JG, Bestvina CM, Berry LD, Owonikoko TK, Sanborn RE, et al. Phase I/II study of nivolumab plus vorolanib in patients with thoracic malignancies: interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts. J Clin Oncol. 2021;39(15_suppl):2578. [Crossref]